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Abstract  
Background  Intensive lifestyle intervention trials in type 2 diabetes contribute  evidence on 
what can be achieved under optimal conditions, but are less informative for translation  in 
applied settings. 
Purpose  Living Well with Diabetes (LWWD) is a telephone-delivered weight loss 
intervention designed for real-world delivery. 
Methods  Randomized controlled trial of telephone counseling (n=151) versus usual care (n= 
151); six-month primary outcomes of weight, physical activity, HbA1c; secondary diet 
outcomes; analysis by adjusted generalized linear models. 
Results  Relative to usual care, telephone counseling participants had small, but significantly, 
better: weight loss (-1.12% of initial body weight, 95% CI: -1.92, -0.33%); physical activity 
(Relative Rate [RR]=1.30, 95% CI: 1.08, 1.57); energy intake reduction (-0.63 MJ/day, 95% 
CI: -1.01, -0.25); and diet quality (3.72 points, 95% CI: 1.77, 5.68), with no intervention 
effect for HbA1c (RR=0.99, 95% CI: 0.96, 1.01). 
Conclusions   Results are discussed in light of challenges to intervention delivery. 
 
Keywords   Type 2 diabetes, Randomized controlled trial, Physical activity, Diet 
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Introduction 
The rapid increase in the prevalence of type 2 diabetes, obesity and associated complications 
is a major public health problem in most developed and many developing countries (1). In 
Australia, data from the 1999-2000 AusDiab study estimated that approximately 1 million 
(7.4%) Australian adults aged 25 years and over have type 2 diabetes (2), while 60% are 
overweight or obese (3), similar to prevalence rates reported in the USA (4) and UK (5).  
Weight loss and physical activity are first line approaches in the treatment of type 2 
diabetes and its related morbidities (6, 7). There is substantial evidence that intensive, and 
most often, clinic-based, lifestyle interventions involving frequent participant contact will 
produce significant weight loss (5-7% of body weight) as well as concomitant improvements 
in glycemic control and dyslipidemia in those with type 2 diabetes (8-10). The Look AHEAD 
trial in the USA, which evaluated a multi-year, intensive lifestyle intervention with the aim of 
reducing the incidence of cardiovascular disease events in type 2 diabetes, is a landmark trial 
in this regard (11). However, the intensity of resources involved in intervention delivery and 
the often highly selected nature of trial participants limits the generalizability of findings 
from such studies (12). While these trials have made substantial contributions to the evidence 
on what is possible to achieve under optimal conditions, they are less informative about what 
is feasible to achieve in applied settings. 
Type 2 diabetes is managed predominately in the primary care setting, with an emphasis 
on monitoring glycemic control and cardiovascular and neurological complications, with 
concomitant medication management. While lifestyle advice is part of guideline concordant 
care (13), intensive lifestyle intervention is not routinely feasible in the general practice 
setting. Patients are often referred to hospital or community-based weight loss/lifestyle 
programs, but only a minority of patients with type 2 diabetes attend (14), and such programs 
are not universally available outside of major metropolitan areas. Thus, there is a need for 
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feasible, effective, broad reach approaches to support the growing numbers of patients with 
type 2 diabetes to achieve and maintain glycemic control via weight loss and improved 
physical activity.
 
 
Telephone-delivered lifestyle interventions have the potential for widespread and cost-
effective population reach and for integration as a primary care referral source. Two 
systematic reviews have found very strong support for their efficacy in improving physical 
activity and dietary behaviors, both in healthy adults and those with chronic conditions (15, 
16). A growing number of trials have evaluated telephone-delivered interventions specifically 
targeting weight loss, with many demonstrating significant intervention effects compared to a 
control group (17-20). Only a small number of trials have evaluated telephone-delivered 
diabetes self-management interventions (21-26). Most had a primary emphasis on medication 
management, with less emphasis on weight loss and changes in behaviors that are 
recommended as part of diabetes management (i.e., physical activity and diet; (13)). The 
consistency of reporting on weight loss and related health behaviors was also mixed in these 
trials, as were results for these outcomes. In addition, limited attention was given to sample 
representativeness.  
This paper describes the six-month outcomes of the Living Well with Diabetes (LWWD) 
trial which is evaluating a telephone-delivered behavioral weight loss intervention targeting 
improved glycemic control in adults with type 2 diabetes recruited from primary care 
practices, compared to usual care. As in the Look AHEAD trial, medical management and 
related medication adherence issues were the domain of the primary care physician or 
specialist, allowing LWWD to work in concert with primary care to provide a lifestyle-
focussed intervention not possible to be delivered in the context of busy primary care visits. 
The six-month endpoint in the LWWD trial corresponds to the end of the intensive phase of 
intervention involving the highest call frequency, with a 12-month maintenance phase to 
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follow. As described in detail elsewhere (27), intervention protocols were adapted for 
telephone delivery from clinical practice guidelines for overweight and obesity (6, 9); our 
previous trial (28); and protocols used in the Look AHEAD trial (29, 30). Thus the LWWD 
trial is a pragmatic trial (31); designed to inform translation of intensive lifestyle change and 
weight loss interventions, such as Look AHEAD, into a feasible broad reach delivery model. 
It was predicted that compared to usual care, telephone counseling would result in greater 
changes in the primary outcomes of weight loss, increased physical activity and improved 
glycemic control; and, in reduced energy intake and improved diet quality. 
 
Methods 
Trial methods are described here in brief, as they have been presented in detail previously 
(27). Living Well with Diabetes is a two-arm randomized controlled trial. Ethical approval 
was granted from The University of Queensland Behavioral and Social Sciences Ethical 
Review Committee. Participants were recruited from nine general practices in the city of 
Logan (population 270,000), a large ethnically and socioeconomically diverse community in 
the state of Queensland (Australia), 35 kilometres from Brisbane (the state capital), an urban 
centre of 1.8 million residents.   
 
Patient recruitment and randomization 
Within practices, 1407 eligible patients (i.e., diagnosed type 2 diabetes; aged 20–75 years; 
and having a listed telephone number) were identified using electronic medical records 
(Figure 1). Patients not initially excluded by General Practitioner (GP) screening for 
contraindications to unsupervised physical activity (n=499) were posted study materials by 
the GP and if not declining further contact (n=206), were followed up by study staff to 
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ascertain eligibility and to solicit informed consent. Patients were eligible if they were 
inactive (self-reported <5 days/week of ≥30min planned exercise) and/or overweight or obese 
(body mass index [BMI] ≥25.0 kg/m2), did not currently use weight loss medications and no 
previous or planned bariatric surgery. Of the potential participants who were able to be 
reached via telephone and were established to be eligible (n=420), 302 (71.9%) agreed to 
participate, completed the baseline assessment and were randomized to receive either 
Telephone Counseling or Usual Care.  
Randomization was by the minimization method (32) using the MINIM program 
(www.sghms.ac.uk/depts/phs/guide/randser.htm). The minimization method aimed to balance 
treatment groups across the following prognostic factors (without weighting for importance): 
gender; age (≥ 55 years); BMI (≥ 40 kg/m2); HbA1c (≥ 8%); self-reported physical activity 
level (meeting guidelines of ≥150 minutes and ≥5 days per week) (33); and, self-reported 
diabetes management (i.e., insulin or combination therapy, traditional oral hypoglycemic 
medications, new agents, or lifestyle alone). Glucagon-like peptide-1 receptor agonists (e.g. 
Exenatide) and dipeptidyl peptidase-4 inhibitors (e.g. Sitagliptin) were considered separately 
as these new agents may cause less weight gain than traditional diabetes medications (34, 35). 
 
Usual Care  
Usual Care participants were mailed a brief summary of their assessment results following 
each assessment, as well as standard, off-the-shelf diabetes self-management education 
brochures. 
 
Telephone-delivered weight loss intervention 
The weight loss intervention, delivered entirely over the telephone, used a combined 
approach of increasing physical activity, reducing energy intake and behavioral therapy (6, 
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9). Participants received a detailed workbook at the commencement of the intervention and 
approximately 14 telephone calls over the first six months (4 initial weekly calls followed by  
fortnightly calls), to support initiation of weight loss. The intervention followed a 
motivational interviewing approach (36) grounded in Social Cognitive Theory constructs of 
self-efficacy, social support and outcome expectancies (6, 9), and emphasized building 
participant skills in behavior change strategies. Accordingly, telephone counsellors worked 
with participants to identify the benefits of weight loss and lifestyle change, set goals for 
small, gradual changes to physical activity and dietary intake, self-monitor progress, 
problem-solve, utilize available supports, and focus on achievements with appropriate 
rewards (6, 37). Specific intervention targets for weight loss, physical activity and dietary 
intake were consistent with management goals for type 2 diabetes (13), with the aim to 
reduce glycosylated haemoglobin (HbA1c) to less than 7% (6, 38, 39). Participants were 
encouraged to achieve moderate weight loss of 5–10% of initial body weight, with a loss of 
1–2 kg per month (13, 40). A target of at least 210 minutes per week (30 minutes every day) 
of moderate-intensity, planned activity was recommended, consistent with the level of 
physical activity necessary to promote weight loss (39), along with resistance exercise (2–3 
sessions/week) (41). To allow for specific food preferences and approaches, individualised 
advice (6, 13, 42) was used to encourage participants to reduce daily energy intake by 2 
megajoules (MJ) by following healthy eating principles, including following a low-fat diet 
(i.e., total fat < 30% of energy and saturated fat < 7% of energy) with sufficient dietary fiber 
(25 grams/day for women and 30 grams/day for men) (43). Participants were provided with a 
pedometer to monitor daily steps and with a set of digital scales to monitor their body weight.  
Fidelity of intervention delivery was monitored via feedback to counselors following 
randomly taped telephone calls and fortnightly clinical supervision meetings. Call attempts, 
completions and duration were tracked in the trial database.  
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Primary and secondary outcomes and data collection 
Primary outcomes were weight, accelerometer-derived moderate to vigorous intensity 
physical activity and HbA1C. Secondary outcomes were energy intake and diet quality. Data 
were collected at baseline and six months via nurse home visits and telephone interviews by 
registered nurses and research staff blind to participants’ group allocation. Weight was 
measured in duplicate, without shoes or heavy clothing, using standard calibrated scales 
(Model TI TBF 350, Tanita Inc., Tokyo, Japan) to the nearest 0.1 kg. Height was measured in 
duplicate at baseline only using a portable stadiometer (Seca 214 height rod, Seca, Germany). 
Blood samples were taken by registered nurses early in the morning after an overnight fast (at 
least 10 hours), with participants instructed not to take any glucose-lowering medication prior 
to the assessment. Current diabetes medications were recorded. HbA1c was measured from 
whole blood samples by the high performance liquid chromatography method (Bio-Rad 
Variant II, Sydney, Australia). 
Nurses provided participants with a GT1M accelerometer (Actigraph, LLC, Fort Walton 
Beach, Florida) to collect physical activity data. This activity monitor, which primarily 
detects ambulatory movement, was fitted firmly around the waist by elasticised band and 
positioned on the right mid axillary line. Monitors were set to record in one minute epochs. 
Participants were instructed to wear the monitor at all times while awake (except during 
water based activities) for a continuous period of seven days, and to record time worn in a 
log. Wear time was ascertained by research staff, who compared the monitor data with 
participants’ wearing logs to determine the precise times movement stopped or began that 
coincided with participant self-reported wear/removal periods.  Using SAS 9.2 (SAS Institute 
Inc., Cary, NC), moderate to vigorous activity was identified as time spent at ≥1952 counts 
per minute (cpm; (44)) during worn time on valid days (i.e., ≥10 hours of wear, without any 
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excessive counts ≥20,000 cpm). Mean moderate to vigorous activity on valid days was 
multiplied by seven to yield a weekly estimate of physical activity, with at least one valid day 
of wear required. Accelerometer compliance was high, with almost all participants (98%; 
97%; 297/302) and 6-month completers (264/272) providing at least 4 valid days of data at 
baseline and 6-months, respectively. Mean (±standard deviation) daily wear time was 
13.5±1.6 hours at baseline and 13.7±1.7 at 6-months.  
Telephone interviews included a previously validated food frequency questionnaire that 
asked about intake over the previous month (Dietary Questionnaire for Epidemiological 
Studies, version 2, Cancer Council Victoria, Australia). The questionnaire estimates intakes 
of most nutrients and energy accurately (within 10%) and does not systematically under- or 
over-estimate against weighed records (45). Coupled with the NUTTAB95 nutrient 
composition database (46), this questionnaire was used to derive average daily energy intake 
and nutrient intake. Overall dietary quality was summarised in terms of the revised Diet 
Quality Index score (47, 48), which ranges from 0 (worst) to 100 (best) quality in terms of 10 
dietary characteristics – total fat, saturated fat, dietary cholesterol, fruit, vegetables, grains, 
calcium, iron, dietary diversity and dietary moderation – relative to current Australian dietary 
recommendations in the version used here (49, 50). Demographic data were also collected 
during the telephone interview.  
 
Statistical Analyses  
Analyses were performed in SPSS version 20.0 (IBM Corp). Significance was set at p<0.05, 
two-tailed. The sample size had been chosen to ensure at least 90% power (with two-tailed 
significance of 5%) to detect minimum differences of interest in primary outcomes of 5% 
weight loss, 0.6% HbA1c and 60 minutes/week physical activity and provided adequate 
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(≥80%) power for differences in diet (2 MJ energy intake and ½ a standard deviation diet 
quality). The trial was not powered apriori for moderation analyses. 
Significance of changes within groups was assessed by paired t-tests (normal data) or 
signed ranks test (physical activity). Analyses were by generalized linear models with normal 
distribution and identity link for data that followed an approximately normal distribution 
(weight loss, log-transformed HbA1c, energy intake and diet quality) or with a gamma 
distribution and log link for physical activity, which approximately followed a gamma 
distribution.  Means for each groups and differences between groups are reported with 
corresponding 95% confidence intervals from these models. Means for HbA1c are presented 
as back-transformed means; for HbA1c and physical activity, differences between groups are 
presented in exponentiated form, as rate ratios (RR, i.e., ratio of mean for Telephone 
Counseling / Usual Care). There was no evidence of collinearity (variance inflation factors all 
< 2.5) or outliers (Cook’s distance < 1). Plots of residuals versus predicted values suggested 
no problems due to non-normality or heteroscedasicity. Models adjusted for baseline values, 
potential confounders partly controlled through minimization (i.e., baseline age, gender, 
HbA1c, BMI, accelerometer-assessed physical activity, nurse-assessed diabetes medications), 
progression onto diabetes medication or onto insulin from baseline to six months, and other a 
priori identified potential confounders that had some association with at least one outcome at 
p<0.1 (i.e., baseline employment (retired yes/no), smoking status (never- /ex-/ current), 
cardiovascular related condition (cardiovascular disease, stroke, hypertension, high 
cholesterol), musculoskeletal condition (arthritis, osteoporosis) and lung disease). Duration of 
diabetes, income, education, use of weight loss aids and depression/anxiety had no 
association at p<0.1 with any outcome; intervention effects were unchanged (to within 20%) 
by removal of these variables from models. Moderation of weight loss by participant 
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characteristics and baseline behaviours was examined by adding interaction terms to the 
models; only results of p<0.1 are reported. 
Missing data (12.6% Telephone Counseling, 7.3% Usual Care) were handled using the 
baseline-value-carried-forward (BVCF) method, to bias results towards the null in view of 
the possible systematic loss of participants who were not benefitting from the program. 
Completers analysis (n=136 Telephone Counseling, n=141 Usual Care) examined the extent 
to which results were affected by assuming no change among dropouts (i.e., BVCF). A per-
protocol analysis (in completers) examined results for those who completed the majority of 
the telephone counseling program (i.e. ≥11 calls).  
 
Results  
Baseline characteristics of the study participants are detailed in Table 1. The sample had a 
mean (± Standard Deviation, SD) age of 58.0 (± 8.6) years and a median duration of diabetes 
of five years (25th, 75th percentile: 2, 10 years). Nearly all participants were either 
overweight (26.2%) or obese (68.2%), over two-thirds were not engaging in guideline levels 
of physical activity (69.5%), most were Caucasian (87.4%) and 56.3% were men. Compared 
with the general diabetes population as reported from the large Australian Diabetes and 
Lifestyle (AusDiab) study, study participants were similar in terms of gender, use of insulin, 
median duration of diabetes and HbA1c, but were more likely to use traditional oral 
hypoglycemic medication (Electronic Supplementary Material (ESM) Table 1), and, 
consistent with the study inclusion criteria, were slightly younger and less variable in age, 
more commonly obese and had a lower prevalence of cardiovascular disease. Participation 
rate was high (72% of those reached and eligible) and participants mostly did not differ from 
non-participants (ESM Table 2) except for statistically significant differences in self-report-
derived BMI, smoking status, educational level and diabetes duration. Loss to follow-up was 
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minimal and non-differential, with 87.4% of the telephone counseling group and 92.7% of the 
usual care group completing all 6-month assessments (Figure 1). Most characteristics did not 
differ between those with complete (n=272) and those with missing data at 6-months (n=30) 
(ESM Table 3); the only statistically significant differences were in use of insulin (p=0.023) 
and smoking status (p=0.036).  
 Table 2 shows the mean values at baseline and follow-up for the outcome variables, and 
the results of the regression analyses that examined intervention effects, adjusted for baseline 
values and potential confounders. There were statistically significant differences between 
groups at follow-up, favoring the telephone counseling group, in weight loss, physical 
activity, energy intake and diet quality, but not in HbA1c. The intervention effects showed, 
relative to usual care, that the intervention group achieved: more weight loss (-1.12% of 
initial body weight, 95% CI: -1.92, -0.33, which was equivalent to -1.14 kg); 30% higher 
mean physical activity (95% CI: 8%, 57%), equating to an absolute difference of 30.8 
minutes per week; and, lower energy intakes (-0.63 MJ, 95% CI: -1.01, -0.25) coupled with 
better dietary quality (3.72 points, 95% CI: 1.77, 5.68). Expressed as Cohen’s d, the adjusted 
between-group differences at follow-up were ‘small’ for weight loss (d=-0.322, 95% CI: -
0.548, -0.094), physical activity (d=0.322, 95% CI: 0.095, 0.549) and diet (energy intake d= -
0.382, 95% CI: -0.610, -0.154; diet quality d=0.439, 95% CI: 0.211, 0.667). For all these 
outcomes, the telephone counseling group improved significantly from baseline while the 
usual care group showed no substantial or significant changes. Despite the behavioral and 
anthropometric improvements, there was no substantial or statistically significant difference 
between groups in HbA1c at follow-up (RR=0.99, 95% CI: 0.96, 1.01, equivalent to an 
absolute difference in means of 0.10 in favor of the telephone counseling group), with no 
significant change from baseline being observed in either telephone counseling or usual care 
groups.  
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Viewed in terms of program targets, few telephone counseling (12.6%) and even fewer 
usual care (4.6%) participants met the program target for weight loss of ≥5% of initial body 
weight (Figure 2a), with most experiencing either minor weight loss (1 to <5% loss) or no 
change (±1%). Weight gain (≥1% of bodyweight) was much less common in the telephone 
counseling (17.2%) than the usual care participants (34.4%). While the program had no 
significant impact on HbA1c, the proportion of participants meeting the HbA1c target (≤ 7) 
(Figure 2b) showed a slight tendency towards a favorable increase in the telephone 
counseling group (+2.7%) and towards a decrease in the usual care group (-5.0%). According 
to accelerometer measures, 27.2% of telephone counseling and 19.2% of usual care 
participants met program targets for physical activity (≥210 minutes per week) at 6-months, 
with these figures having been at 17.9% and 17.2%, respectively at baseline (Figure 2c). Only 
a minority (19.9% of telephone counseling and 17.2% of usual care) met the targeted 2 MJ 
reduction in energy intake (Figure 2d).  
Sensitivity analyses showed significant intervention effects for physical activity were still 
present (RR=2.09, 95% CI: 1.39, 3.15, absolute difference = 17.4 minutes) when applying 
one of the highest cutpoints for moderate physical activity (≥2743 cpm) (51), but not when 
applying one of the lowest moderate cutpoints, designed to capture lifestyle activities (51) 
(RR=1.03, 95% CI: 0.92, 1.12, absolute difference = 25.3 minutes), which also led to 
unrealistic mean estimates of physical activity (approximately 13 hours per week).  
Sensitivity analyses in completers showed that BVCF had either reduced the differences 
between groups or had not affected results for: weight loss (-1.27, 95% CI: -2.14, -0.40 % of 
initial weight); HbA1c (RR=0.99, 95% CI: 0.96, 1.02, absolute difference =0.09); physical 
activity (RR=1.29, 95% CI:1.06, 1.57, absolute difference = 31.0 minutes per week); energy 
intake (-0.71, 95% CI:-1.12, -0.30 MJ); and diet quality (4.28, 95% CI: 2.16, 6.39 points). 
BVCF can underestimate the variability in the outcomes but did so only slightly in this study. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
The standard errors for intervention effects using BVCF were all 92% the size of those in 
completers and widening the 95% confidence intervals for the BVCF results accordingly did 
not alter study conclusions regarding statistical significance. 
Those in the telephone counseling group received from none to 17 calls over the first six 
months (median = 10; 25
th
, 75
th
 percentile: 6,12), with 46% receiving the majority of calls 
(≥11) and 91 participants (60.3%) receiving the majority of the four initial weekly calls. 
Mean (SD) call duration was 28.2 (11.2) minutes. Call receipt was not significantly 
associated with most participant characteristics, except for employment, with retirees 
receiving the most calls (ESM Table 4).  
Per protocol analyses showed that differences in outcomes for the telephone counseling 
participants who completed the majority of calls (n=68), relative to the usual care (n=141), 
were much stronger than in the main analysis or completers analysis: weight loss (-2.17, 95% 
CI: -3.24, 1.10 % of initial weight); HbA1c (RR=0.96, 95% CI: 0.93, 1.00, p=0.056, absolute 
difference = -0.26); physical activity (RR=1.44, 95% CI: 1.13, 1.83, absolute difference = 
47.1 minutes per week); energy intake (-0.71, 95% CI: -1.22, -0.21 MJ); and, diet quality 
(5.72, 95% CI: 3.27, 8.2 points). There was a statistically significant (p=0.027) reduction in 
HbA1c within the telephone counseling participants adhering to protocol, with means (95% 
CI) shifting from 7.3 (7.0, 7.6) at baseline to 7.1 (6.9, 7.3) at follow-up.  
We did not detect significant (p<0.05) moderation of weight loss by age, gender, 
race/ethnicity, country of birth, BMI, duration of diabetes, medication use, CVD, 
musculoskeletal conditions, lung, smoking status, employment, education, baseline HbA1c, 
physical activity, energy intake, dietary quality. The only results meeting our reporting 
threshold (p<0.1) were for race/ethnicity (p=0.062) and country of birth (p=0.063).  
Intervention effects (95%CI) on percent weight loss were -1.46 (-2.32, -0.59)% and 0.90  
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(-1.38, 3.18)% respectively, in Caucasians (n=118) and non-Caucasians (n=38), and were -
1.62 (-2.59, -0.62)% and 0.02 (-1.40, 1.43)% in those born in Australia (n=89) and elsewhere 
(n=47). 
Given small effect sizes, rather than formal mediation analyses, associations of potential 
mediators with outcomes were examined. Within the intervention group, significant 
associations with HbA1c improvements were seen for weight loss (Spearman’s R=0.34, 95% 
CI: 0.48, 0.18, p<.001), increased physical activity (Spearman’s R=0.19, 95% CI: 0.03, 0.35, 
p=0.025) but not reductions in energy intake (Spearman’s R=0.01, 95% CI: -0.17, 0.18,  
p=0.953). Similarly, a significant association with weight loss was seen for increased 
physical activity (Spearman’s R=0.23, 95% CI: 0.03, -0.19, p=0.007) but not reduced energy 
intake (Pearson’s R=0.15, 95% CI:-0.02, 0.31 p=0.084). 
   
Discussion 
LWWD was designed as a pragmatic trial to determine the weight loss, increased physical 
activity, glycemic control and dietary-change outcomes that could be achieved when the 
approach used in intensive interventions - such as the landmark Diabetes Prevention Program 
and Look AHEAD trials - was adapted for delivery via telephone and implemented with a 
largely representative primary care sample of adults with type 2 diabetes. Six-month results, 
from the end of the intensive phase of the LWWD intervention, demonstrated small, 
statistically significant improvements in weight loss, objectively measured moderate-to-
vigorous physical activity, and dietary outcomes in the intervention group relative to the 
controls. However, there were no significant intervention effects for HbA1c.  
Overall, as expected given the less intensive LWWD intervention protocol, intervention 
effects were considerably less than those reported after one year in the Look AHEAD trial, 
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which equated to a difference between intensive lifestyle intervention versus diabetes 
education of -7.9% of initial bodyweight (95% CI:-8.2, -7.6) for weight loss and -0.50 (95% 
CI: -0.56, -0.44) for HbA1c. A review and meta-analysis of lifestyle and behavioral weight 
loss intervention studies in adults with type 2 diabetes published up until 2003 indicated that 
compared with usual care, lifestyle-based interventions resulted in a pooled mean weight loss 
of 3.1% of initial body weight (95% CI:-4.5, -1.7), and a pooled mean reduction in HbA1c of 
0.3 (95% CI:-0.8, 0.2) (10). LWWD results for weight loss are closer to these, although still 
not as strong, but it is important to note that all of the studies in this review were delivered 
via face-to-face contacts, either in individual or group format, or some combination. Similar 
attenuation of intervention effects has been observed as intensive diabetes prevention 
interventions, like the US and Finnish Diabetes Prevention Programs (52, 53), have been 
evaluated in translational settings (54). The weight loss achieved in LWWD (1.14 kg) was 
consistent with the pooled mean weight loss (relative to control) of 1.82 kg (95% CI:-2.70, -
0.99 kg) (54) reported in a recent meta-analysis of seven diabetes prevention translational 
trials that used randomized designs.  
Six trials have used the telephone, solely or in combination with other modalities, for 
delivering diabetes self-management interventions in participants with type 2 diabetes (21-
26), and with intervention duration ranging from 6 to 12 months. Of the four trials assessing 
weight loss, only one reported significant intervention effects, of -4.0 kg (95% CI:-7.3, -0.7) 
(22). The non-significant effect sizes were -0.8 kg (95% CI:-2.3, 0.7) (23), -1.4 kg (21) and 
not reported (25). Despite these weight loss outcomes being of similar magnitude to our 
findings, these telephone-delivered trials achieved better results for glycemic control, 
possibly owing to a focus on medication adherence, with all but one (25) reporting significant 
intervention effects for HbA1c, ranging from -0.4 (95% CI:-0.70, -0.10; (26)) to -1.2 (95% 
CI: -1.8, -0.6; (24)).  
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Intervention improvements in physical activity were associated with weight loss, and 
weight loss was, in turn, associated with improved glycaemic control. However, the 
percentages of LWWD telephone group participants meeting the intervention targets for 
physical activity and diet (i.e., ≥210 min/week MVPA and at least 2MJ/day reduction in 
energy intake), while tending to improve with intervention, were quite low. This may partly 
explain the small intervention effect for weight loss and, in turn, the lack of improvement in 
glycemic control. Consistently, the results for the telephone counseling participants who had 
received the majority of calls were more positive than the results for the telephone counseling 
group as a whole, with more behavioral improvement, greater weight loss and some 
suggestion of a benefit in terms of glycemic control.  
Strengths of the LWWD trial include attention to rigorous trial methods, specifically  
appropriate randomization, the blinding of assessors, use of objective and validated 
measurement for all outcomes (except diet), low attrition, high accelerometer compliance, 
and the evaluation of the robustness of the findings to assumptions regarding missing data 
and accelerometer cutpoints. Further, this was a pragmatic trial that delivered an intervention 
feasible for uptake to what was, for the most part, a representative sample of Australian 
primary care patients with type 2 diabetes. Limitations were: some minor participation biases 
typical in trials (i.e., a slight over-representation of those with higher education, never-
smokers and those who were heavier and more recently diagnosed with diabetes);  the use of 
a food frequency questionnaire to measure energy intake (55), which was chosen over the 
preferred 24-hour dietary recall method due to resource limitations; and the fact that the 
activity monitor primarily captures ambulatory movement while tending to underestimate 
participation in other activities, particularly strength training, which was encouraged as part 
of the intervention. Also, the way in which call attempt data were recorded in the database 
did not allow us to determine with certainty the extent to which low call completion related to 
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lack of participant engagement versus non-delivery by counselors; however, examination of 
counselor-kept call records suggests that the vast majority of missed calls were due to 
participants.  
While telephone-delivered lifestyle interventions show promise as a broad reach delivery 
modality relevant to the growing numbers of adults with type 2 diabetes, six-month results 
from the LWWD trial were quite small. As a trial designed to inform translation, we sought 
to recruit and retain a representative sample of participants, rather than a selected group of 
more motivated participants. This resulted in a sizeable proportion of intervention group 
participants not sufficiently engaged with the intervention to derive significant benefit, 
despite the motivational interviewing approach, and thus with small intervention effects for 
the intervention group as a whole. In contrast, intervention effects for those who participated 
in most of the program were considerably stronger. Taken together, results suggest that if the 
LWWD intervention were to be delivered only to willing/motivated participants in a 
translational setting, the impacts on weight, behavior change and glycemic control may be 
substantially stronger than is indicated by the findings from this trial. In future research, it 
may be advisable to screen potential participants prior to program enrollment to solicit a 
commitment to engage fully in all intervention activities, including all scheduled calls – 
perhaps not to the extent of the formal ‘run-in’ periods implemented in the landmark 
intervention trials, but certainly more than the ‘take all comers’ approach used here. The risk 
of such screening is that it may act to exclude the more socioeconomically disadvantaged and 
racial/ethnic minority groups. Notably, the only socio-demographic characteristic 
significantly associated with call completion was employment status (being retired). As this 
type of intervention research moves increasingly into translational settings, it will be 
important to balance the need for wide population reach and representativeness with the 
imperative to allocate scarce healthcare resources to those likely to benefit. Interim results 
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from the LWWD trial suggest that consideration should be given to culturally-tailored 
programs, and perhaps to less individually-targeted approaches that might better reach those 
from non-Caucasian backgrounds.  Subsequent reporting on end-of-intervention and 
maintenance outcomes, and cost-effectiveness analyses will be important to speak to the full 
potential to inform translation. 
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Figure Captions 
Fig. 1 Flow diagram of study participation  
Fig. 2 Percentage of telephone counseling (n=151) and usual care (n=151) participants at 6-
month follow up: in each weight loss category (a); meeting glycemic control 
recommendations (b); achieving study physical activity targets (c); and, meeting study targets 
for energy intake reduction (d)
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Table 1 Baseline characteristics of study participants randomized to Telephone Counseling 
(n=151) and Usual Care (n=151) 
 Telephone 
Counseling 
(n=151) 
 Usual Care 
(n=151) 
 
 
All  
(n=302) 
Age, years, mean (SD)  57.7 (8.1) 
 
   58.3 (9.0)  58.0 (8.6) 
Male n (%)     84 (55.6) 
 
   86 (57.0)   170 (56.3) 
Body Mass Index, mean (SD) 33.1 (6.3) 
 
33.2 (6.0)     33.1 (6.1) 
Overweight/obese, n (%)  141 (93.4%)  144 (95.4%)  285 (94.4%) 
Duration diabetes, years, median 
(25
th
, 75
th
 percentile) 
4.0 
(2.0, 7.0)  
5.0 
(2.0, 10.0)  
5.0 
(2.0,10.0) 
Diabetes medication 
a
 
   
  
   Traditional OHAs, n (%)   114 (75.5) 
 
 119 (78.8)   233 (77.2) 
   Insulin, n (%)     23 (15.2) 
 
   20 (13.2)     43 (14.2) 
   Newer agents, n (%)       7 (4.6) 
 
     5 (3.3)     12 (4.0) 
Other chronic conditions 
   
  
   CVD related condition, n (%)   127 (84.1) 
 
 113 (74.8)   240 (79.5) 
   Musculoskeletal condition, n (%) 51 (33.8) 
 
   50 (33.1)   101 (33.4) 
   Lung condition, n (%)     14 (9.3) 
 
   18 (11.9)     32 (10.6) 
Smoking status, n (%)      
Never smoker      77 (51.0)  67 (44.4)   144 (47.7) 
Ex-smoker     60 (39.7)  67 (44.4)   127 (42.1) 
Current smoker     14 (9.3)  17 (11.3)     31 (10.3) 
Born in Australia, n (%)     99 (65.6) 
 
 108 (71.5)   207 (68.5) 
Caucasian, n (%)   131 (86.8)   133 (88.1)   264 (87.4) 
Employment, n (%)      
Full-/Part- time or casual     97 (64.3) 
 
93 (61.6)   190 (62.9) 
Retired     40 (26.5)  42 (27.8)     82 (27.2) 
Other     14 (9.3)  16 (10.6)     30 (9.9) 
Income <$1000/week, n (%)      49 (32.5) 
 
61 (40.4)   110 (36.4) 
< High school education, n (%)       9 (6.0) 
 
26 (17.2)     35 (11.6) 
HbA1c, median (25
th
, 75
th
 
percentile) 
7.6 
(6.3, 8.5) 
 
7.0 
(6.4, 7.9)  
7.1 
(6.4,8.0) 
Physical activity
 b
, mins/week, 
median (25
th
, 75
th
 percentile) 
93.5 
(28.8, 151.9) 
 
92.2 
(39.2, 185.1)  
92.7 
(38.4, 180.5) 
Sufficiently active (150 
mins/week)
b
, n (%) 
   47 (31.1%)     45 (29.8%) 
 
  92 (30.5%) 
Energy intake, mean (SD)   7.1 (2.3)    6.9 (2.2)       7.0 (2.2) 
Diet Quality (0-100), mean (SD)   65.6 (13.6)     65.5 (10.7)     65.6 (11.0) 
a 
OHAs = oral hypoglycemic medications; new agents = glucagon-like peptide-1 receptor 
agonists (e.g. Exenatide) or dipeptidyl peptidase-4 inhibitors (e.g. Sitagliptin); CVD = 
cardiovascular disease  
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b 
Accelerometer moderate to vigorous physical activity, time spent at ≥1952 counts per 
minute  1  2 
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Table 2 Six-month outcomes for participants randomized to Telephone Counseling (n=151) and Usual Care (n=151), adjusted for 
baseline values and potential confounders 
a
 
  Telephone Counseling (n=151)  Usual Care (n=151)  Telephone Counseling vs Usual Care 
  Mean (SD or 95% CI)  Mean (SD or 95% CI)  Coefficient (95% CI)  p 
Weight          
Baseline weight, kg             94.5 (18.7)          95.3 (20.1)     
6-month weight, kg             93.3 (19.0)*         95.3 (20.9)     
6-month weight loss, adjusted, 
% of initial weight 
             -1.3 (-1.8, -0.7)          -0.2 (-0.7, 0.4)  -1.12 (-1.92, -0.33)  .006 
Accelerometer physical activity, 
mins/week
 b
 
        
Baseline            125.2 (114.7)       120.2 (113.9)     
6-months           164.0 (160.4)*       122.0 (109.1)     
6-months, adjusted   133.9 (117.8, 152.3)  102.9 (90.5, 117.0)  RR = 1.30 (1.08, 1.57)  .005 
HbA1C, % 
        
Baseline                7.4 (1.5)           7.5 (1.7)     
6-months               7.5 (1.7)           7.5 (1.6)     
6-months, adjusted
 b, c
               7.3 (7.1, 7.4)           7.4 (7.2, 7.5)  RR = 0.99 (0.96, 1.02)  .355 
Diet Quality Index, 0-100 points 
        
Baseline              65.8 (11.4)         65.3 (10.7)     
6-months             69.4 (12.1)*         65.6 (11.0)     
6-months, adjusted             69.4 (68.0, 70.7)  65.7 (64.3, 67.0)       3.72 (1.77, 5.68)  <.001 
Energy intake, MJ 
        
Baseline                6.9 (2.2)           7.1 (2.3)     
6-months               6.2 (2.1)*           7.0 (2.2)     
6-months, adjusted               6.3 (6.0, 6.5)           6.9 (6.6, 7.2)  -0.63 (-1.01, -0.25)  .001 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
32 
 
Table presents baseline and 6 month unadjusted means (Standard Deviations, SD) and adjusted means (95% Confidence Intervals, CI) 
within groups and between-groups differences at 6-months, with results derived from generalized linear models assuming a normal 
distribution and identity link, or gamma distribution with log link for physical activity.  
a
 models adjust for baseline values of the outcome, potential confounders partly controlled through minimization (age, gender, Body 
Mass Index [BMI], accelerometer physical activity, HbA1C, traditional oral hypoglycemic use, insulin use, use of new agents), 
employment (retired yes/no), smoking status (never, ex-smoker, current smoker), cardiovascular condition (cardiovascular disease, 
stroke, hypertension or high cholesterol), musculoskeletal condition (arthritis or osteoporosis) and lung condition (e.g. emphysema, 
asthma, chronic bronchitis) and progression onto diabetes medication or onto insulin between baseline and 6-months. Weight loss 
models adjust for baseline weight rather than baseline BMI; physical activity models further adjusted for accelerometer wear time and 
changes in wear time.
 
b 
Coefficient (95% CI) presented in exponentiated form as relative rate (RR) 
c
 Outcome was log transformed; adjusted means (95% CI) are presented in back-transformed form 
* significant change (within groups) from baseline (paired t-test) p<0.05 
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1,407 T2DM patients identified from electronic medical 
records (from 9 practices) 
1105 Excluded 
499 screened out by GP 
206 declined further contact 
215 ineligible 
   67   unable to contact 
 118   refused (78 not interested, 17  
          illness, 17 no reason, 6 other) 
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A
n
a
ly
si
s 
151 Randomized to Telephone  
       Intervention 
151 Randomized to Usual Care  
148 Received intervention (1+ 
calls) (median 10 calls, range 
1 – 17) 
3  Uncontactable 
151 Received Usual Care 
 
144  Remained in study 
    7 Withdrew from study 
4   Not interested  
 1 Illness  
 2  Other 
 
 
135  Remained in study 
  16 Withdrew from study  
 7  Not interested  
 2  Illness  
 5  Other 
 2  Uncontactable 
 
151  Patients included in primary analysis 
 
Baseline values carried forward for 
withdrawals/missing data: 
 13  Nurse visit (weight, HbA1c) 
 16  Accelerometer   
 13  CATI (diet quality, energy intake) 
 
151  Patients included in primary analysis 
 
Baseline values carried forward for 
withdrawals/missing data: 
 10  Nurse visit (weight, HbA1c) 
 11  Accelerometer 
 10  CATI (diet quality, energy intake) 
 
302 Randomized 
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ESM Table 1 Socio-demographic and clinical characteristics of Living Well With Diabetes 
(LWWD) participants compared with the general diabetes population in the Australian 
Diabetes, Obesity and Lifestyle (AusDiab) study 
 Diabetes Population (AusDiab) 
 
LWWD  
 Diabetes  n  Value (n=302)  p 
a
 
Age, years, mean (SD)
b
 Type 2  393    64 (15.9)   58.0 (8.6)  <.001 
Male, n (%)
b
 Type 2  393  220 (56)  170 (56.3)  .939 
BMI, kg/m
2
 mean (SD)
c
 Type 1&2  425    30.0 (6.2)   33.1 (6.1)  <.001 
Obesity (BMI ≥30), n (%)b Type 2  393  185 (47)  206 (68.2)  <.001 
HbA1C, mean (SD)
d
 Type 2  439      7.3 (1.8)     7.5 (1.6)   .121 
Cardiovascular disease, n (%)
c
 Type 1&2  425  122 (28.7)   34 (11.3)  <.001 
Diabetes management
e
          
   Insulin, n (%) Type1&2  396    71 (17.9)  43 (14.2)   .215 
   Oral hypoglycemics, n (%) Type1&2  396  230 (58.2)  233 (77.2)  <.001 
Duration of diabetes, years, 
median (25
th
, 75
th
 %ile)
e
 Type1&2  396      5 (2, 12)     5 (2, 10)  - 
a
 p for difference between LWWD and the diabetes population based on independent samples 
t-test for mean (Standard Deviation, SD) or Fisher’s Exact chi-square test for n (%) 
b 
reported in Tapp, Dunstan, et al. (56)  
c
 reported in Barr et al. (57)  
d
 reported in Kemp et al. (58)  
e
 reported in Tapp, Zimmet, et al. (59)  
 
Table
ESM Table 2 Comparison of study participants with non-participants on demographic, 
health, and behavioral characteristics 
  Non-participants  Participants 
(n=302) 
 p
 a
 
 n  value 
Age, years, mean (SD) 111  58.4 (10.3)    58.0 (8.6)    .681 
Male, n (%) 115  58 (50.4)  170 (56.3)    .322 
Non-participant Questionnaire        
BMI (self-report), mean (SD) 64  30.64 (4.76)    32.3 (6.1)    .040 
Self-report diabetes management, n (%)
b
        
Insulin 63 
 
12 (19.0)    44 (14.6) 
 
  .441 
Traditional OHAs 63 
 
43 (68.3)  231 (76.5) 
 
  .200 
New agents 63 
 
  2 (3.2)      7 (2.3) 
 
  .657 
Lifestyle only 63 
 
11 (17.5)    55 (18.2) 
 
>.999 
Born in Australia, n (%) 63 
 
35 (55.6)  207 (68.5) 
 
  .057 
Caucasian, n (%) 61 
 
51 (83.6)  264 (87.4) 
 
  .411 
3+ chronic conditions, n (%) 66 
 
46 (69.7)  184 (60.9) 
 
  .208 
Smoking status, n (%) 63 
 
   
 
<.001 
Never smoker 
  
  5 (7.9)  144 (47.7) 
 
 
Ex-smoker 
  
51 (81.0)  127 (42.1) 
 
 
Current smoker 
  
  7 (11.1)    31 (10.3) 
 
 
Employment status, n (%) 63        .173 
Full-time/ Part-time/Casual   32 (50.8)  190 (62.9)   
Retired   21 (33.3)    82 (27.2)   
Other   10 (15.9)    30 (9.9)   
< High School Education, n (%) 63 
 
16 (25.4)    35 (11.6) 
 
  .008 
Income <$1000/week, n (%) 55  21 (38.2%)  110 (36.9)    .880 
        
Diabetes Duration, median (25th, 75th 
percentile) 63 
 
 
  7.0  
 (4.0, 11.0)  
    5.0  
  (2.0, 10.0) 
 
  .005 
≥5 days/week of ≥30 mins PA, n (%)c 66  13 (19.7)    57 (19.0)    .864 
a 
p for difference between participants and non-participants by chi-square test for n (%), 
independent samples t-test for mean (Standard deviation, SD), or independent samples 
median test for median (25
th
, 75
th
 percentile)
 
b 
OHAs = oral hypoglycemic medications; new agents = glucagon-like peptide-1 receptor 
agonists (e.g. Exenatide) or dipeptidyl peptidase-4 inhibitors (e.g. Sitagliptin) 
c
 Due to missing data, n=300 participants for days per week of at least 30 minutes of physical 
activity (PA), a single item screening question asked of most participants and in the non-
participant questionnaire 
 
Table
ESM Table 3 Comparison of completers (n=272) with those missing 6-month study 
outcomes (n=30) 
 
 
Missing data 
(n=30, 9.93%) 
 
Completer 
(n=272) 
 p 
a
 
Telephone Counseling, n (%)  19 (63.3)  132 (48.5)  .177 
Age, years, mean (SD)  58.0 (9.2)    58.0 (8.5)  .973 
Male, n (%) 
 
13 (43.3)  157 (57.7) 
 
.174 
Diabetes management       
   Using Insulin, n (%) 
 
  9 (30.0)    34 (12.5) 
 
.023 
   Using traditional OHAs, n (%) 
 
25 (83.3)  208 (76.5)  .496 
Diabetes duration, median (25
th
, 75
th
 
percentile) 
   6.0 (2.75, 10.0)      4.0 (2.0, 9.8)  .172 
3+ Chronic conditions, n (%)  20 (66.7)  164 (60.3)  .559 
Smoking status, n (%)      .036 
Never smoker  12 (40.0)  132 (48.5)   
Ex-smoker  10 (33.3)  117 (43.0)   
Current smoker    8 (26.7)    23 (8.5)   
Born in Australia, n (%)  20 (66.7)  187 (68.8)  .837 
Caucasian, n (%)  28 (93.3)  236 (86.8)  .396 
Income <$1000/week, n (%)  12 (40.0)    98 (36.0)  .692 
< High school education, n (%) 
 
  2 (6.7)    33 (12.1) 
 
.551 
Employment, n (%)      .788 
Full-time/ Part-time/casual 
 
20 (66.7)  170 (62.5) 
 
 
Retired    8 (26.7)    74 (27.2) 
 
 
Other    2 (6.7)    28 (10.3) 
 
 
Body Mass Index, kg/m
2
, mean (SD)  33.7 (8.5)    33.1 (5.8) 
 
.683 
HbA1C, median (25
th
, 75
th
 percentile)    7.6 (6.3, 8.5)      7.0 (6.4, 7.9)  .218 
Physical activity
 b
, mins/week, median 
(25
th
, 75
th
 percentile)
 
 
 93.5 (28.8, 151.9)   92.2 (39.2, 185.1)  .847 
Energy intake, MJ, mean (SD) 
 
  6.5 (2.1)      7.0 (2.3) 
 
.229 
Diet Quality Index, 0-100, mean (SD) 
 
65.6 (13.6)    65.5 (10.7) 
 
.977 
a 
p for difference between those missing data and completers by chi-square test for n (%), 
independent samples t-test for mean (Standard deviation, SD), or independent samples 
median test for median (25
th
, 75
th
 percentile) 
b 
Accelerometer moderate to vigorous physical activity, time spent at ≥1952 counts per 
minute 
 
Table
ESM Table 4 Association of baseline characteristics with call receipt and 6-month weight 
loss (as percentage of initial weight) within the telephone counseling group 
 n Number of calls  p 
Age, years  151 rs=0.017 .840 
Gender                                                           Male    84 10.0 (6.0, 12.0) .379 
                             Female   67 10.0 (6.0, 12.0)  
Body Mass Index 151 rs=0.088 .281 
Duration diabetes, years 151 rs=0.065 .426 
Diabetes medication 
a
 151   
Traditional Oral Hypoglycemic Agents           yes 114 10.0 (6.0, 12.0) .951 
                                     no   37 10.0 (6.5, 12.0)  
Insulin                                                              yes   23 10.0 (5.0, 12.0) .948 
                                     no 128 10.0 (6.25, 12.0)  
Other chronic conditions    
CVD related                                                     yes 127 10.0 (6.0, 12.0) .558 
                                    no   24 10.0 (5.25, 12.0)  
Musculoskeletal                                               yes   51 10.0 (5.0, 12.0) .231 
                                     no 100 10.0 (7.0, 12.0)  
Lung                                                                 yes   14 10.0 (5.75, 11.0) .650 
                                     no 137 10.0 (6.0, 12.0)  
Smoking status   .380 
Never smoker    77 10.0 (7.0, 12.5)  
Ex-smoker   60 11.0 (6.0, 12.0)  
Current smoker   14   9.0 (4.75, 11.25)  
Born in Australia                                              yes   99 10.0 (7.0, 13.0) .752 
                                     no   52 10.0 (5.25, 12.0)  
Caucasian                                                         yes 131 10.0 (6.0, 12.0) .091 
                                     no 20   8.0 (5.25, 8.0)  
Employment   .029 
Full-/Part- time or casual   97 10.0 (6.0, 12.0)  
Retired   40 11.5 (9.0, 13.0)  
Other   14 10.0 (6.0, 10.25)  
Income                                             <$1000/week             49 11.0 (8.5, 13.0) .230 
     ≥ $1000/week/missing 102   9.0 (5.75, 12.0)  
Education                                        < High school        9   8.0 (4.5, 11.5) .283 
                   ≥High school          142 10.0 (6.0, 12.0)  
HbA1c 151 rs=0.033 .685 
Physical activity
 a
 151 rs=0.023 .778 
Energy intake 151 rs=0.072 .378 
Diet Quality (0-100) 151 rs=0.023 .777 
Table presents median (25
th
, 75
th
 percentile) number of calls or mean (SD) weight loss, 
Spearman’s correlations (rs) or Pearson’s correlation (rp) 
 
Table
a 
Accelerometer moderate to vigorous physical activity, time spent at ≥1952 counts per 
minute 
 
